Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, MD PhD, Martin Hutchings, MD PhD, Riikka Räty, MD PhD, Karin Fahl Wader, MD PhD, Anna Laurell, MD PhD, Jacob H. Christensen, MD, Hanne Kuitunen, MD, Christian Winther Eskelund, MD PhD, Kirsten Groenbaek, MD DMSc, Carsten Utoft Niemann, MD PhD, Christian H. Geisler, MD PhD, Arne Kolstad, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-133298

Published: 2020

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Mats Jerkeman, MD PhD, Arne Kolstad, MD PhD, Carsten Utoft Niemann, MD PhD, Kirsten Groenbaek, MD DMSc, Martin Hutchings, MD PhD, Annika Pasanen, MD PhD, Sara Ekberg, Karin Fahl Wader, MD PhD, Ingrid Glimelius, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133273

Published: 2020

Journal Articles

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Sabina Kersting, MD PhD, Mark-David Levin, MD PhD, Carsten Utoft Niemann, MD PhD, Yvette Norden, PhD, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 1753.

https://doi.org/10.1182/blood-2019-124550

Published: 2019

Journal Articles

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Kathrine Aarup, Lisbeth Enggaard, MD, Robert Schou Pedersen, MD PhD, Rasmus Heje Thomsen, Olav Jonas Bergmann, Mikael Frederiksen, Ilse Christiansen, Tine Nielsen, Henrik Frederiksen, MD Prof, Carsten Utoft Niemann, MD PhD Ass. Prof, Michael Asger Andersen, MD

Blood (2019) 134 (Supplement_1): 1767.

https://doi.org/10.1182/blood-2019-123011

Published: 2019

Journal Articles

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Caspar Da Cunha-Bang, MD PhD, Rudy Agius, Arnon P. Kater, Mark-David Levin, MD PhD, Anders Österborg, MD PhD, Mattias Mattsson, MD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4304.

https://doi.org/10.1182/blood-2019-121907

Published: 2019

Journal Articles

Mapping Comorbidity in CLL: Impact on Prognostic Factors, Treatment Patterns and Causes of Death

Emelie Curovic Rotbain, MD, Carsten Utoft Niemann, MD PhD Ass. Prof, Klaus Rostgaard, MSc., Caspar Da Cunha-Bang, MD PhD, Henrik Hjalgrim, MD Dr.MD, Henrik Frederiksen, MD Prof

Blood (2019) 134 (Supplement_1): 4285.

https://doi.org/10.1182/blood-2019-122673

Published: 2019

Journal Articles

Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients

Rebecka Svanberg, MD, Sisse Rye Ostrowski, MD PhD DMSc, Ass Prof, Jakob Thaning Bay, MD PhD, Lars Peter Ryder, MSc, PhD, Hanne Vibeke Vibeke Marquart, Arnon P Kater, MD PhD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4289.

https://doi.org/10.1182/blood-2019-123410

Published: 2019

Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Blood (2019) 134 (Supplement_1): 4292.

https://doi.org/10.1182/blood-2019-124377

Published: 2019

Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 4312.

https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312

Published: 2017

Journal Articles

Prediagnostic Progression of Lymphocytosis in Chronic Lymphocytic Leukemia Is Predictive of Progression Free Survival As Early As Five Years Prior to Diagnosis

Michael Asger Andersen, MD, Mia Klinten Grand, Volkert Siersma, Niels Olivarius, Christen Lykkegaard Andersen, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 1726.

https://doi.org/10.1182/blood.V130.Suppl_1.1726.1726

Published: 2017

Journal Articles

IGHV Mutation Status and Outcome in CLL Patients Treated with Chemoimmunotherapy: A Nationwide Analysis

Emelie Curovic Curovic Rotbain, MD, Caspar Da Cunha-Bang, MD PhD, Henrik Hjalgrim, Klaus Rostgaard, MSc., Michael A Andersen, MD, Carsten Utoft Niemann, MD PhD, Henrik Frederiksen, associate professor, consultant, PhD

Blood (2017) 130 (Supplement 1): 1742.

https://doi.org/10.1182/blood.V130.Suppl_1.1742.1742

Published: 2017

Journal Articles

Bacterial Infections in Patients with Chronic Lymphocytic Leukemia: A Longitudinal Nation-Wide Study

Michael Asger Andersen, MD, Caspar Da Cunha-Bang, MD PhD, Marie Helleberg, MD PhD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 3461.

https://doi.org/10.1182/blood.V130.Suppl_1.3461.3461

Published: 2017

NARROW

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Mapping Comorbidity in CLL: Impact on Prognostic Factors, Treatment Patterns and Causes of Death

Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Prediagnostic Progression of Lymphocytosis in Chronic Lymphocytic Leukemia Is Predictive of Progression Free Survival As Early As Five Years Prior to Diagnosis

IGHV Mutation Status and Outcome in CLL Patients Treated with Chemoimmunotherapy: A Nationwide Analysis

Bacterial Infections in Patients with Chronic Lymphocytic Leukemia: A Longitudinal Nation-Wide Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only